Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Grant

Showing results (341-350 of 386) with videos related to

Pageof 39
Sort By:
Molecular Pharmacology|November 14, 2009
Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cellsAdly Yacoub, Renyan Liu, Margaret A Park, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Blood|February 7, 2016
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDRLiang Zhou, Shuang Chen, Yu Zhang, et al.
Discovery Medicine|February 1, 2011
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinicRupesh Dash, Belal Azab, Xue-Ning Shen, et al.
Leukemia & Lymphoma|December 28, 2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndromeBeata Holkova, Danielle Shafer, Victor Yazbeck, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 26, 2011
The role of Tyk2 in regulation of breast cancer growthQifang Zhang, Jamie L Sturgill, Maciej Kmieciak, et al.
Cancer Research|June 14, 2012
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapiesShuang Chen, Yun Dai, Xin-Yan Pei, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 2, 2013
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safetySuzanne J Suchard, Patricia M Davis, Selena Kansal, et al.
Cancer Research|May 31, 2011
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cellsM Danielle Bareford, Margaret A Park, Adly Yacoub, et al.
Pageof 39

Showing results (341-350 of 386) with videos related to

Sort By:
Pageof 39
Molecular Pharmacology|November 14, 2009
Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cellsAdly Yacoub, Renyan Liu, Margaret A Park, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Blood|February 7, 2016
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDRLiang Zhou, Shuang Chen, Yu Zhang, et al.
Discovery Medicine|February 1, 2011
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinicRupesh Dash, Belal Azab, Xue-Ning Shen, et al.
Leukemia & Lymphoma|December 28, 2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndromeBeata Holkova, Danielle Shafer, Victor Yazbeck, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 26, 2011
The role of Tyk2 in regulation of breast cancer growthQifang Zhang, Jamie L Sturgill, Maciej Kmieciak, et al.
Cancer Research|June 14, 2012
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapiesShuang Chen, Yun Dai, Xin-Yan Pei, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 2, 2013
A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safetySuzanne J Suchard, Patricia M Davis, Selena Kansal, et al.
Cancer Research|May 31, 2011
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cellsM Danielle Bareford, Margaret A Park, Adly Yacoub, et al.
Pageof 39